388 related articles for article (PubMed ID: 18798265)
1. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
[TBL] [Abstract][Full Text] [Related]
3. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
[TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
6. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
7. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
9. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
10. IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
Carter SL; Centenera MM; Tilley WD; Selth LA; Butler LM
BMC Cancer; 2016 Feb; 16():141. PubMed ID: 26907477
[TBL] [Abstract][Full Text] [Related]
11. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
Washington MN; Weigel NL
Endocrinology; 2010 Apr; 151(4):1409-17. PubMed ID: 20147525
[TBL] [Abstract][Full Text] [Related]
12. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
Liu S; Qi Y; Ge Y; Duplessis T; Rowan BG; Ip C; Cheng H; Rennie PS; Horikawa I; Lustig AJ; Yu Q; Zhang H; Dong Y
Mol Cancer Ther; 2010 Jul; 9(7):2016-25. PubMed ID: 20571066
[TBL] [Abstract][Full Text] [Related]
13. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
[TBL] [Abstract][Full Text] [Related]
15. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
16. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
17. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
18. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
19. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
